South Korea's New CDMO Special Act Enhances Biologics Manufacturing Capacity
- The Korea CDMO Special Act, effective 31 December 2026, streamlines licensing and GMP certification for biologics manufacturers.
- LOTTE Biologics has completed its 120,000-liter Songdo Plant 1 six months ahead of schedule, enhancing local capacity.
Operational Impact
LOTTE Biologics' early completion of its Songdo facility adds significant capacity, supporting the growing demand for biologics manufacturing in Korea.
Source: PharmaSource RSS